Contribution of metabolic disease to bone fragility in MAGP1-deficient mice

S. E. Turecamo, T. A. Walji, T. J. Broekelmann, J. W. Williams, S. Ivanov, N. K. Wee, J. D. Procknow, M. R. McManus, G. J. Randolph, E. L. Scheller, R. P. Mecham, C. S. Craft

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Microfibril-associated glycoprotein-1 (MAGP1) is an extracellular matrix protein that interacts with fibrillin and is involved in regulating the bioavailability of signaling molecules such as TGFβ. Mice with germline MAGP1 deficiency (Mfap2 −/− ) develop increased adiposity, hyperglycemia, insulin resistance, bone marrow adipose tissue expansion, reduced cancellous bone mass, cortical bone thinning and bone fragility. The goal of this study was to assess whether the Mfap2 −/− bone phenotypes were due to loss of MAGP1 locally or secondary to a change in whole body physiology (metabolic dysfunction). To do this, mice with conditional deletion of MAGP1 in the limb skeleton were generated by crossing MAGP1-flox mice (Mfap2 lox/lox ) with Prx1-Cre mice. Mfap2 Prx−/− mice did not show any changes in peripheral adiposity, hyperglycemia or insulin sensitivity, but did have increased bone length and cancellous bone loss that was comparable to the germline Mfap2 −/− knockout. Unlike the germline knockout, marrow adiposity, cortical bone thickness and bone strength in Mfap2 Prx−/− mice were normal. These findings implicate systemic metabolic dysfunction in the development of bone fragility in germline Mfap2 −/− mice. An unexpected finding of this study was the detection of MAGP1 protein in the Mfap2 Prx−/− hematopoietic bone marrow, despite the absence of MAGP1 protein in osseous bone matrix and absent Mfap2 transcript expression at both sites. This suggests MAGP1 from a secondary site may accumulate in the bone marrow, but not be incorporated into the bone matrix, during times of regional MAGP1 depletion.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalMatrix Biology
Volume67
DOIs
StatePublished - Apr 1 2018

Fingerprint

Metabolic Bone Diseases
Adiposity
Bone Marrow
Bone and Bones
Bone Matrix
Hyperglycemia
Insulin Resistance
Tissue Expansion
microfibrillar protein
Extracellular Matrix Proteins
Bone Development
Skeleton
Biological Availability
Adipose Tissue
Proteins
Extremities
Phenotype

Keywords

  • Bone
  • Bone fracture
  • Diabetes
  • Fibrillin
  • MAGP1
  • Marrow adipose tissue
  • Microfibrils
  • Obesity
  • Skeletal fragility

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Cite this

Turecamo, S. E., Walji, T. A., Broekelmann, T. J., Williams, J. W., Ivanov, S., Wee, N. K., ... Craft, C. S. (2018). Contribution of metabolic disease to bone fragility in MAGP1-deficient mice. Matrix Biology, 67, 1-14. https://doi.org/10.1016/j.matbio.2018.02.022

Contribution of metabolic disease to bone fragility in MAGP1-deficient mice. / Turecamo, S. E.; Walji, T. A.; Broekelmann, T. J.; Williams, J. W.; Ivanov, S.; Wee, N. K.; Procknow, J. D.; McManus, M. R.; Randolph, G. J.; Scheller, E. L.; Mecham, R. P.; Craft, C. S.

In: Matrix Biology, Vol. 67, 01.04.2018, p. 1-14.

Research output: Contribution to journalArticle

Turecamo, SE, Walji, TA, Broekelmann, TJ, Williams, JW, Ivanov, S, Wee, NK, Procknow, JD, McManus, MR, Randolph, GJ, Scheller, EL, Mecham, RP & Craft, CS 2018, 'Contribution of metabolic disease to bone fragility in MAGP1-deficient mice', Matrix Biology, vol. 67, pp. 1-14. https://doi.org/10.1016/j.matbio.2018.02.022
Turecamo, S. E. ; Walji, T. A. ; Broekelmann, T. J. ; Williams, J. W. ; Ivanov, S. ; Wee, N. K. ; Procknow, J. D. ; McManus, M. R. ; Randolph, G. J. ; Scheller, E. L. ; Mecham, R. P. ; Craft, C. S. / Contribution of metabolic disease to bone fragility in MAGP1-deficient mice. In: Matrix Biology. 2018 ; Vol. 67. pp. 1-14.
@article{edefa08a8d6941a5be87ab0d531841f5,
title = "Contribution of metabolic disease to bone fragility in MAGP1-deficient mice",
abstract = "Microfibril-associated glycoprotein-1 (MAGP1) is an extracellular matrix protein that interacts with fibrillin and is involved in regulating the bioavailability of signaling molecules such as TGFβ. Mice with germline MAGP1 deficiency (Mfap2 −/− ) develop increased adiposity, hyperglycemia, insulin resistance, bone marrow adipose tissue expansion, reduced cancellous bone mass, cortical bone thinning and bone fragility. The goal of this study was to assess whether the Mfap2 −/− bone phenotypes were due to loss of MAGP1 locally or secondary to a change in whole body physiology (metabolic dysfunction). To do this, mice with conditional deletion of MAGP1 in the limb skeleton were generated by crossing MAGP1-flox mice (Mfap2 lox/lox ) with Prx1-Cre mice. Mfap2 Prx−/− mice did not show any changes in peripheral adiposity, hyperglycemia or insulin sensitivity, but did have increased bone length and cancellous bone loss that was comparable to the germline Mfap2 −/− knockout. Unlike the germline knockout, marrow adiposity, cortical bone thickness and bone strength in Mfap2 Prx−/− mice were normal. These findings implicate systemic metabolic dysfunction in the development of bone fragility in germline Mfap2 −/− mice. An unexpected finding of this study was the detection of MAGP1 protein in the Mfap2 Prx−/− hematopoietic bone marrow, despite the absence of MAGP1 protein in osseous bone matrix and absent Mfap2 transcript expression at both sites. This suggests MAGP1 from a secondary site may accumulate in the bone marrow, but not be incorporated into the bone matrix, during times of regional MAGP1 depletion.",
keywords = "Bone, Bone fracture, Diabetes, Fibrillin, MAGP1, Marrow adipose tissue, Microfibrils, Obesity, Skeletal fragility",
author = "Turecamo, {S. E.} and Walji, {T. A.} and Broekelmann, {T. J.} and Williams, {J. W.} and S. Ivanov and Wee, {N. K.} and Procknow, {J. D.} and McManus, {M. R.} and Randolph, {G. J.} and Scheller, {E. L.} and Mecham, {R. P.} and Craft, {C. S.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.matbio.2018.02.022",
language = "English (US)",
volume = "67",
pages = "1--14",
journal = "Matrix Biology",
issn = "0945-053X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Contribution of metabolic disease to bone fragility in MAGP1-deficient mice

AU - Turecamo, S. E.

AU - Walji, T. A.

AU - Broekelmann, T. J.

AU - Williams, J. W.

AU - Ivanov, S.

AU - Wee, N. K.

AU - Procknow, J. D.

AU - McManus, M. R.

AU - Randolph, G. J.

AU - Scheller, E. L.

AU - Mecham, R. P.

AU - Craft, C. S.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Microfibril-associated glycoprotein-1 (MAGP1) is an extracellular matrix protein that interacts with fibrillin and is involved in regulating the bioavailability of signaling molecules such as TGFβ. Mice with germline MAGP1 deficiency (Mfap2 −/− ) develop increased adiposity, hyperglycemia, insulin resistance, bone marrow adipose tissue expansion, reduced cancellous bone mass, cortical bone thinning and bone fragility. The goal of this study was to assess whether the Mfap2 −/− bone phenotypes were due to loss of MAGP1 locally or secondary to a change in whole body physiology (metabolic dysfunction). To do this, mice with conditional deletion of MAGP1 in the limb skeleton were generated by crossing MAGP1-flox mice (Mfap2 lox/lox ) with Prx1-Cre mice. Mfap2 Prx−/− mice did not show any changes in peripheral adiposity, hyperglycemia or insulin sensitivity, but did have increased bone length and cancellous bone loss that was comparable to the germline Mfap2 −/− knockout. Unlike the germline knockout, marrow adiposity, cortical bone thickness and bone strength in Mfap2 Prx−/− mice were normal. These findings implicate systemic metabolic dysfunction in the development of bone fragility in germline Mfap2 −/− mice. An unexpected finding of this study was the detection of MAGP1 protein in the Mfap2 Prx−/− hematopoietic bone marrow, despite the absence of MAGP1 protein in osseous bone matrix and absent Mfap2 transcript expression at both sites. This suggests MAGP1 from a secondary site may accumulate in the bone marrow, but not be incorporated into the bone matrix, during times of regional MAGP1 depletion.

AB - Microfibril-associated glycoprotein-1 (MAGP1) is an extracellular matrix protein that interacts with fibrillin and is involved in regulating the bioavailability of signaling molecules such as TGFβ. Mice with germline MAGP1 deficiency (Mfap2 −/− ) develop increased adiposity, hyperglycemia, insulin resistance, bone marrow adipose tissue expansion, reduced cancellous bone mass, cortical bone thinning and bone fragility. The goal of this study was to assess whether the Mfap2 −/− bone phenotypes were due to loss of MAGP1 locally or secondary to a change in whole body physiology (metabolic dysfunction). To do this, mice with conditional deletion of MAGP1 in the limb skeleton were generated by crossing MAGP1-flox mice (Mfap2 lox/lox ) with Prx1-Cre mice. Mfap2 Prx−/− mice did not show any changes in peripheral adiposity, hyperglycemia or insulin sensitivity, but did have increased bone length and cancellous bone loss that was comparable to the germline Mfap2 −/− knockout. Unlike the germline knockout, marrow adiposity, cortical bone thickness and bone strength in Mfap2 Prx−/− mice were normal. These findings implicate systemic metabolic dysfunction in the development of bone fragility in germline Mfap2 −/− mice. An unexpected finding of this study was the detection of MAGP1 protein in the Mfap2 Prx−/− hematopoietic bone marrow, despite the absence of MAGP1 protein in osseous bone matrix and absent Mfap2 transcript expression at both sites. This suggests MAGP1 from a secondary site may accumulate in the bone marrow, but not be incorporated into the bone matrix, during times of regional MAGP1 depletion.

KW - Bone

KW - Bone fracture

KW - Diabetes

KW - Fibrillin

KW - MAGP1

KW - Marrow adipose tissue

KW - Microfibrils

KW - Obesity

KW - Skeletal fragility

UR - http://www.scopus.com/inward/record.url?scp=85042868713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042868713&partnerID=8YFLogxK

U2 - 10.1016/j.matbio.2018.02.022

DO - 10.1016/j.matbio.2018.02.022

M3 - Article

C2 - 29519758

AN - SCOPUS:85042868713

VL - 67

SP - 1

EP - 14

JO - Matrix Biology

JF - Matrix Biology

SN - 0945-053X

ER -